Side-by-side · Research reference

LL-37vsVesugen

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AHuman-MechanisticHUMAN-REVIEWED15/35 cited

BAnimal-MechanisticHUMAN-REVIEWED5/43 cited

LL-37

Cathelicidin · Human AMP

Broad-spectrumAntimicrobial activity

Membrane disruptionPrimary mechanismLu 2026 He 2026

Innate immunityHost defense rolePinheiro 2026 Zhang 2026

Endogenous · Secreted at inflammation sites

Vesugen

Bioregulatory Tripeptide · Vascular Endothelium

3 AATripeptide

Endothelin-1 ↓Atherosclerotic tissue

Ki-67 ↑Aged endothelium

SQ / IM · Protocol varies

01Mechanism of Action

Parameter

LL-37

Vesugen

Primary target

Bacterial membranes · Phosphatidylserine-exposed cellsHe 2026 Lu 2026

Vascular endothelial cell nucleus — MKI67 gene promoter

Pathway

hCAP-18 precursor → Proteinase-3 cleavage → LL-37 release → Membrane insertion/disruption

KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑

Downstream effect

Membrane permeabilization, cytokine induction, autophagy, phagosome-lysosome fusion, chemotaxisAhmad 2026 Zhang 2026

Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016 Khavinson 2014

Feedback intact?

—

Not applicable — does not operate via hormone axis

Origin

Endogenous human cathelicidin (37-AA fragment, residues 134–170 of hCAP-18)

Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator

Antibody development

—

02Dosage Protocols

Parameter

LL-37

Vesugen

Endogenous expression

Constitutive in neutrophils, epithelial tissues

Upregulated during infection and inflammation.Pinheiro 2026

—

Exogenous (experimental)

Dose varies by study; antimalarial ~10–50 μM in vitro

No FDA-approved exogenous formulation.

—

Plasma levels (malaria)

Elevated in infected patients and miceHe 2026

Exogenous administration reduced parasitemia in murine models.He 2026

—

Evidence basis

In vitro, animal models, human observational

Animal models (atherosclerosis, restenosis, aging) · Russian case series

Standard dose (reported)

—

Not standardised — Russian clinical case series

Protocols vary; no FDA-approved regimen.

Route

—

Subcutaneous or intramuscular

Frequency

—

Not specified in available literature

Duration

—

Case series report treatment courses in elderly arterial insufficiency

Half-life

—

Not reported

Tripeptides typically cleared rapidly.

04Side Effects & Safety

Parameter

LL-37

Vesugen

Cytotoxicity (high dose)

Membrane disruption in host cells at supraphysiological concentrations

—

Pro-inflammatory signaling

Can exacerbate inflammation in certain contexts (context-dependent)Pinheiro 2026

—

Biofilm formation risk

LL-37-DNA complexes may stabilize dental plaque biofilmsTanabe 2026

—

Theoretical cancer risk

Immunomodulatory roles in tumor microenvironment under investigation

—

Reported adverse events

—

None documented in available abstracts

Injection site

—

Assumed minimal — typical for small peptides

Long-term safety

—

Unknown — no long-term RCT data

Epigenetic mechanism risk

—

Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised

Absolute Contraindications

LL-37

—

Vesugen

—

Relative Contraindications

LL-37

·Active autoimmune disease (theoretical immune dysregulation)

Vesugen

·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context

05Administration Protocol

Parameter

LL-37

Vesugen

1. Natural secretion

LL-37 is constitutively expressed in neutrophils and epithelial cells, cleaved from hCAP-18 by proteinase-3 at sites of infection or inflammation.

Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.

2. Experimental formulations

Synthetic LL-37 and derivatives (e.g., SAMP-12aa) tested in vitro and animal models. Administered via topical, intraperitoneal, or intravenous routes in research settings.

Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.

3. Stability considerations

LL-37 is resistant to pepsin degradation at gastric pH. Synthetic short peptides designed to retain this stability while reducing toxicity.Lu 2026

No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.

4. Storage

—

Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).

06Stack Synergy

LL-37

— no documented stacks

Vesugen

+ Thymalin

Multi-pathway

View Thymalin →

Both from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.

Vesugen: Per protocol (SQ/IM)
Thymalin: Per protocol (SQ/IM)
Frequency: Sequential or concurrent per geroprotective protocol
Primary benefit: Multi-system age-related decline mitigation (vascular + immune)